Preliminary Evidence of Intratumoral Activation and Immunomodulatory Effect of CX-072, a Probody Therapeutic Antibody Prodrug Targeting PD-L1, in a Phase 1/2 Trial

Susan K. Lyman, Judi Gordon, Amy DuPage, Preeti Pramanik, Bruce Howng, Ivan A. Zein, Michael B. Winter, Irina K. Popova, Olga Vasiljeva, James Jones, Ken Wong, Victoria Singson, Jennifer Richardson, Beiyao Zheng, Mark Stroh, Lori Carman, Vanessa Huels, Karen Autio, Valentina Boni, Daniel Cho, Javier Garcia-Corbacho, Iván Victoria Ruiz, Omid Hamid, Nataliya Uboha, Elisabeth de Vries, Anthony El-Khoueiry, Alexander Spira, Rachel E. Sanborn, Fiona Thistlethwaite, Hendrik-Tobias Arkenau, Johanna Bendell, Patrick A. Ott, Naiyer Rizvi, Matthias Will, W. Michael Kavanaugh, Aung Naing, Luc R. Desnoyers. Poster presented at SITC 2018, November 7-11, Washington, D.C.